TGF-β inhibition through topical application of small molecule inhibitors has been demonstrated as a therapeutic option in psoriasis, as systemic use of TGF-β inhibitors can lead to severe side effects because of pleiotropic roles of TGF-β in development and homeostasis (29). This evidence concerns the gene TGFB1 and psoriasis.